The expression of TFII-I would be therapeutically beneficial by affecting different TFII-I-mediated regulatory pathways together with BRCA1 and the failure of binding between BRCA1 and TFII-I may be a key event in cancer predisposition. The gene discussed is GTF2I; the disease is cancer.